Advanced Solid Tumors Clinical Trials in Austin, Texas

7 studies are recruiting for advanced solid tumors in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

   The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Austin, Austin, Texas

   Locations

   20 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06657222 on ClinicalTrials.gov

2. A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

   Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main g…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology ( Site 1010), Austin, Texas

   Locations

   49 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06818643 on ClinicalTrials.gov

3. Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

   The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors. The primary objectives of this study are to: * To assess the safety and tolerability of …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Austin, Austin, Texas

   Locations

   8 in total

   Run by

   Gilead Sciences

   See if you can join NCT06167317 on ClinicalTrials.gov

4. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

   Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas at Austin, Austin, Texas

   Locations

   21 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT05379985 on ClinicalTrials.gov

5. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

   A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or tr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Austin, Austin, Texas

   Locations

   9 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06804824 on ClinicalTrials.gov

6. PAS-004 in Patients With Advanced Solid Tumors

   The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate diff…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, Austin, Texas

   Locations

   7 in total

   Run by

   Pasithea Therapeutics Corp.

   See if you can join NCT06299839 on ClinicalTrials.gov

7. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

   This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site 135, Austin, Texas

   Locations

   107 in total

   Run by

   DualityBio Inc.

   See if you can join NCT05914116 on ClinicalTrials.gov